Sponsor Pipeline

Erasca, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
2
Recruiting
1
Phase 3
1
Disease Areas
Active Trials by Phase
Phase 3
1
Phase 1/2
1
Phase 1
4
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06346067 A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With… Advanced or Metastatic NRAS-mutant Melanoma Active, Not Recruiting
Phase 1/2
NCT04866134 A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With… Advanced or Metastatic Solid Tumors Active, Not Recruiting
Phase 1
NCT07021898 A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. Metastatic Solid Tumors Recruiting
NCT06983743 A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors Metastatic Solid Tumors Recruiting
NCT05907304 A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With… Advanced or Metastatic Solid Tumors Active, Not Recruiting
NCT04670679 A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic… Advanced or Metastatic Solid Tumors Active, Not Recruiting
Disease Areas
Melanoma (1)
Get alerts when Erasca, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free